Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, Dec. 17 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces a two-unit sale to a Canadian Hospital.
"For the first time, a client has purchased two units at the same time as
a way to significantly decrease its use of the toxic Ethylene Oxide gas" said
Ann Hewitt, VP Sales & Marketing for TSO3 Inc. "This is eloquent proof that
our sterilizer is the most environmentally and economically attractive method
to replace ETO."
This two-unit purchase was made to transfer the maximum volume of medical
devices from the ETO sterilizers into Ozone Sterilization. The hospital will
be able to remove one ETO unit from its Central Sterilization Department right
now and eventually, to remove the other ETO unit and completely cease the use
of this toxic sterilizing agent in its CS Department.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 72 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical
facts (including, without limitation, those regarding the timing or
outcome of any financing undertaken by TSO3) are forward-looking
statements that involve certain risks, uncertainties and hypotheses,
including, but not limited to, general business and economic conditions,
the condition of the financial markets, the ability of TSO3 to obtain
financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, email@example.com; Source: TSO3